Chinese herbal medicines for adverse events of transarterial chemoembolization in patients with primary liver cancer

  • Protocol
  • Intervention

Authors

  • Xiao-Qian Li,

    Corresponding author
    1. Changhai Hospital, Second Military Medical University, Department of Traditional Chinese Medicine, Shanghai, Shanghai, China
    • Xiao-Qian Li, Department of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical University, Room 1407, Building of Science and Technology, Changhai Hospital, 168 Changhai Road, Shanghai, Shanghai, 200433, China. jcimlxq@yahoo.cn.

    Search for more papers by this author
  • Qinghui Zhou,

    1. Changhai Hospital, Second Military Medical University, Department of Traditional Chinese Medicine, Shanghai, Shanghai, China
    Search for more papers by this author
  • Jian Ping Liu,

    1. Beijing University of Chinese Medicine, Centre for Evidence-Based Chinese Medicine, Beijing, China
    Search for more papers by this author
  • Kun-Ming Tao,

    1. Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Department of Anesthesiology, Shanghai, Shanghai, China
    Search for more papers by this author
  • Hongyun Chen,

    1. Changhai Hospital, Second Military Medical University, Department of Traditional Chinese Medicine, Shanghai, Shanghai, China
    Search for more papers by this author
  • Changquan Ling

    1. Changhai Hospital, Second Military Medical University, Department of Traditional Chinese Medicine, Shanghai, Shanghai, China
    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the benefits and harms of CHM on any adverse events or adverse effects caused by TACE when used for treatment of patients with primary liver cancer.